Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Pa

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. LLY
2. DAVA
3. MONC:IM
4. MONRY
5. NYXH
6. PNR
7. ONON
8. IAUX
9. KKR
10. VICR

Go back to Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Pa
(NASDAQ: VRCA) Delayed: 4.49 --0 (-0%)
Previous Close $4.49    52 Week High $ 
Open $4.49    52 Week Low $ 
Day High $4.49    P/E N/A 
Day Low $4.49    EPS $ 
Volume 50